Compare CSTL & BZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | BZH |
|---|---|---|
| Founded | 2007 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.3M | 672.0M |
| IPO Year | 2019 | 1995 |
| Metric | CSTL | BZH |
|---|---|---|
| Price | $24.90 | $18.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $47.17 | $32.00 |
| AVG Volume (30 Days) | ★ 398.2K | 352.8K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $344,229,000.00 | ★ $2,087,739,000.00 |
| Revenue This Year | $2.42 | $4.36 |
| Revenue Next Year | $12.69 | $10.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $17.37 |
| 52 Week High | $44.28 | $28.33 |
| Indicator | CSTL | BZH |
|---|---|---|
| Relative Strength Index (RSI) | 26.58 | 19.50 |
| Support Level | $24.89 | N/A |
| Resistance Level | $34.97 | $24.10 |
| Average True Range (ATR) | 1.02 | 0.73 |
| MACD | 0.13 | -0.44 |
| Stochastic Oscillator | 4.41 | 0.72 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.